

# How to Diagnose and Treat ATTR Cardiomyopathy: A Primer for Clinical Cardiologists

Sign up for a session

**Tuesday, Nov. 26<sup>th</sup> 2024**

6:00 - 7:00 pm PST

**Monday, Dec. 2<sup>nd</sup> 2024**

7:00 - 8:00 pm AST

**Monday, Dec. 2<sup>nd</sup> 2024**

7:30 - 8:30 pm EST

**Tuesday, Dec. 3<sup>rd</sup> 2024**

7:00 - 8:00 pm EST

ATTR cardiomyopathy is an underdiagnosed condition with high morbidity and mortality. With new disease-modifying treatments available, the prognosis for patients with ATTR cardiomyopathy can be substantially improved. This program will guide cardiologists in how to suspect and confirm diagnosis, which heart failure therapies to avoid using, and how to initiate disease-modifying therapies and obtain drug reimbursement.

## Faculty



**Margot Davis**  
MD, MSc, FRCPC, FCCS

Clinical Associate Professor,  
University of British Columbia  
Vancouver, BC



**Ryan Davey**  
MD, FRCPC, FACC

Associate Professor,  
Division of Cardiology Heart Failure Service,  
Schulich School of Medicine & Dentistry,  
Western University

## Moderator



**Milan Gupta**  
MD, FRCPC, FCCS, CPC (HC)

Assistant Professor, Department of Medicine  
University of Toronto,  
Medical Director,  
Collaborative CME and Research Network  
Brampton, ON

## Learning Objectives

- Review a practical diagnostic approach to ATTR-cardiomyopathy
- Discuss which heart failure therapies to use and to avoid
- Facilitate obtaining coverage and initiating disease-modifying treatments

**Target Audience:** Cardiologists and Internists

Register at:  
[www.ccrnmd.com](http://www.ccrnmd.com)

For program inquiries, contact:  
[info@ccrnmd.com](mailto:info@ccrnmd.com)



This program was developed by the Collaborative CME and Research Network and has received an educational grant from Pfizer.